Novartis AG (ADR) news

   Watch this stock
Showing stories 1 - 9 of about 9   

Articles published

NVS 99.18 +2.69 (2.79%)
price chart
New pharmacovigilance system debuts in EU
The definition of an adverse drug report (ADR) has also been widened to include medical error, off-label use, drug abuse and drug mis-use, and patients across Europe will now be able to report ADRs directly to regulatory authorities. In time, other ...
Related articles »  
Roche Building On Its Strengths
With other drugs like Zelboraf and T-DM1 on the way (Zelboraf is approved, T-DM1 likely will be in 2013), Roche looks poised to stretch its lead on Novartis (NVS), Sanofi, and AstraZeneca in oncology. What's more, while Regeneron's (REGN) Eylea may ...
Top 5 Highest Yielding Zacks #1 Ranked Municipal Bond Mutual Funds
Debt securities will always be the natural choice of the risk-averse investor because this category of instruments provides regular income flow at low levels of risk.
Related articles »  
Developed Asia Pacific ETF Investing 101
Recent years have not been very good for developed markets like the U.S and Europe. A heavy debt burden and high level of unemployment have put pressure on the economic stability of the two regions and could continue to pressure both as the months ...
Related articles »  
FDA Clears Teleflexs Latest PICC
Teleflex Incorporated (TFX - Snapshot Report), a worldwide provider of medical devices has announced the 510(k) clearance from the U.S.
Related articles »  
Enbridge Line 14 Spills Oil
Texas-based Enbridge Energy Partners LP (EEP - Analyst Report) will again be targeted by the safety regulators as crude oil leaked from Line 14, which forms a part of the partnership's Lakehead System.
Related articles »  
Thermo Fisher to Acquire One Lambda
Within one year of the Phadia acquisition (for �2.47 billion), in August 2011, which strengthened the company's Specialty Diagnostics business, Thermo Fisher Scientific (TMO - Analyst Report) yet again announced another strategic move to diversify its ...
Related articles »  
What Patent Cliff? Pharma ETFs Continue to Surge
For at least the past few years, investors in the health care segment have been focused in on big pharma and the segment's fast approaching 'patent cliff'.
Related articles »  
Cosan Completes Comma Acq.
The Zacks Consensus Estimates for the fiscal years 2013 and 2014 stand at 90 cents and $1.61 per ADR, respectively. These estimates reflect a year-over-year decline of 65.39% in 2013 and growth of 78.60% in 2014.
Related articles »